Researchers at Virginia Commonwealth University have found that inhibiting inflammasome formation with P2X7 antagonists could help prevent heart failure following acute myocardial infarction. The findings point to a repurposing opportunity for P2X7 antagonists that companies have in the clinic for inflammatory indications.